Based on clinical evidence, catheter-based renal denervation (RDN) has been proven to significantly reduce various blood pressure measurements, including office blood pressure, home blood pressure, and 24-hour ambulatory blood pressure, regardless of whether patients are treated with antihypertensive medications. Multiple large randomized sham-controlled trials have confirmed the safety and efficacy of RDN, showing particularly excellent results in Asian populations. Several sham-controlled radiofrequency RDN trials conducted in Chinese populations have been published, showing that the reduction in 24-hour ambulatory systolic blood pressure in Chinese populations (approximately －9 mmHg) is superior to that observed in Western trials. Additionally, long-term follow-up studies in China have shown that radiofrequency RDN continues to reduce blood pressures for up to ten years. The best indicators for evaluating RDN efficacy are, in order: morning home blood pressure, nighttime (asleep) blood pressure monitoring, and morning trough office blood pressure. Considering Asian blood pressure characteristics, RDN’s long-term efficacy, and its advantages in 24-hour blood pressure control, RDN should be considered an effective option for Asian hypertensive patients. Currently, China and several other Asian countries and regions have approved RDN for clinical use, and corresponding guidelines have endorsed RDN as an effective treatment option for uncontrolled and resistant hypertension.